[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-336297-105":59,"doc-detail-336297-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","concurrent-inhibition-of-oncogenic-and-wild-type-ras-gtp-for-cancer-therapy","Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy","","RAS oncogenes (NRAS, HRAS and especially KRAS) are frequently mutated across cancers, yet most KRAS mutations lack approved targeted inhibitors beyond KRAS(G12C). The article presents RMC-7977, a reversible tri-complex RAS inhibitor with broad-spectrum activity against active-state mutant and wild-type KRAS, NRAS and HRAS variants. In preclinical RAS-addicted models, RMC-7977 drives tumor regression, is well tolerated, and can inhibit resistant KRAS(G12C) cancers via restored RAS signaling.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/concurrent-inhibition-of-oncogenic-and-wild-type-ras-gtp-for-cancer-therapy/336297/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/concurrent-inhibition-of-oncogenic-and-wild-type-ras-gtp-for-cancer-therapy/336297.png","ImageObject",300,407,{"name":92,"@type":93},"Eliana","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are RAS oncogenes important targets in cancer therapy?","Question",{"text":112,"@type":113},"RAS oncogenes such as NRAS, HRAS, and especially KRAS are among the most commonly mutated genes in cancer. Driver mutations activate RAS signaling by stabilizing the active, GTP-bound (ON) state, promoting oncogenic flux through downstream effectors.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What is RMC-7977 and what does it target?",{"text":117,"@type":113},"RMC-7977 is a reversible tri-complex RAS inhibitor designed to inhibit the active state of both mutant and wild-type RAS variants, including KRAS, NRAS and HRAS.",{"name":119,"@type":110,"acceptedAnswer":120},"How did RMC-7977 perform in preclinical cancer models?",{"text":121,"@type":113},"In RAS-addicted preclinical models, RMC-7977 showed potent anti-tumor activity, including tumor regression, and was well tolerated. It also inhibited growth in KRAS(G12C) models that were resistant to KRAS(G12C) inhibitors by restoring RAS pathway signaling.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},336297,1790194121,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},4398048949847,"https://ap-avatar.wpscdn.com/avatar/400002536579ef2da7f?_k=1778318612642679267","Article  \n\n| Concurrent inhibition of oncogenicand wild-type RAS-GTP for cancer therapy |  |  |\n| --- | --- | --- |\n| [https://doi.org/10.1038/s41586-024-07205-6](https://doi.org/10.1038/s41586-024-07205-6)\u003Cbr>Received: 28 June 2023 Accepted: 16 February 2024 Published online: 8 April 2024 Open access\u003Cbr> Check for updates | Matthew Holderfield1, Bianca J. Lee1, Jingjing Jiang1, Aidan Tomlinson1, Kyle J. Seamon1, Alessia Mira2, Enrico Patrucco2, Grace Goodhart3, Julien Dilly4, Yevgeniy Gindin1, Nuntana Dinglasan1, Yingyun Wang1, Lick Pui Lai1, Shurui Cai1, Lingyan Jiang1,\u003Cbr>Nicole Nasholm1, Nataliya Shifrin1, Cristina Blaj1, Harshit Shah1, James W. Evans1, Nilufar Montazer1, Oliver Lai1, Jade Shi1, Ethan Ahler1, Elsa Quintana1, Stephanie Chang1, Anthony Salvador1, Abby Marquez1, Jim Cregg1, Yang Liu1, Anthony Milin1, Anqi Chen1, Tamar Bar Ziv1, Dylan Parsons1, John E. Knox1, Jennifer E. Klomp5, Jennifer Roth6, Matthew Rees6, Melissa Ronan6, Antonio Cuevas-Navarro7, Feng Hu7, Piro Lito7,8, David Santamaria9, Andrew J. Aguirre4,6,10,11, Andrew M. Waters3,5,12,13, Channing J. Der5,12, Chiara Ambrogio2, Zhengping Wang1, Adrian L. Gill1, Elena S. Koltun1,\u003Cbr>Jacqueline A. M. Smith1 ✉, David Wildes1 ✉ & Mallika Singh1 ✉\u003Cbr>RAS oncogenes (collectively NRAS, HRASand especially KRAS) are among the most frequently mutated genes in cancer, with common driver mutations occurring at codons 12, 13 and 611. Small molecule inhibitors of the KRAS(G12C) oncoprotein have demonstrated clinical efficacy inpatients with multiple cancer types and have led to regulatory approvalsforthe treatment of non-small cell lung cancer2,3. Nevertheless, KRASG12C mutations account for only around 15% ofKRAS-mutated cancers4,5, and there are no approved KRAS inhibitors for the majority of patients with tumours containing other common KRAS mutations. Here we describe RMC-7977, a reversible, tri-complex RAS inhibitor with broad-spectrum activity for the active state of both mutant and wild-type KRAS, NRAS andHRAS variants (aRAS(ON) multi-selective inhibitor). Preclinically, RMC-7977 demonstrated potent activity against RAS-addicted tumours carrying various RAS genotypes, particularly against cancer models with KRAS codon 12 mutations (KRASG12X). Treatment with RMC-7977 led to tumour regression and was well tolerated in diverse RAS-addicted preclinical cancer models. Additionally, RMC- 7977 inhibited the growth ofKRASG12C cancer models that are resistant to KRAS(G12C) inhibitors owing to restoration of RAS pathway signalling. Thus, RAS(ON) multiselective inhibitors can target multiple oncogenicand wild-type RAS isoforms and have the potential totreatawide range of RAS-addicted cancers with high unmet clinical need. A related RAS(ON) multi-selective inhibitor, RMC-6236, is currently under clinical evaluation inpatients with KRAS-mutant solid tumours (ClinicalTrials. gov identifier: NCT05379985). |  |\n| RAS family genes encode small GTPase proteins that regulate cell prolif- |  | functional genetic screening data demonstrated that KRAS-mutated |\n| eration in response to growth factor stimuli1,5. Cancer-associated KRAS |  | cancer cell lines are highly sensitive to disruption of the KRAS locus |\n| mutations are found frequently in non-small cell lung cancer (NSCLC), |  | (Extended Data Fig. 1a), and KRAS mutation status was the only genetic |\n| colorectal cancers (CRC) and pancreatic ductal adenocarcinoma2 |  | feature that exhibited a significant correlation with KRAS dependency |\n| (PDAC), the three leading causes of cancer deaths in the USA6. These |  | (Extended Data Fig. 1b). Similar results were observed for NRASand |\n| activating mutations drive tumour progression by stabilizing the active, GTP-bound (ON) state of RAS proteins and thereby increasing onco- |  | HRASinNRAS-andHRAS-mutated lines, respectively (Extended Data Fig. 1c–f). Furthermore, KRASmutations at position 12 are both the most |\n| genic flux through downstream effectors7. Analysis of CRISPR–Cas9 ","cbCaidtCrGzS1nFL","https://ap.wps.com/l/cbCaidtCrGzS1nFL","pdf",6409529,28,"English","# Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy\n## RMC-7977 discovery and development\n## RAS dependency and genetic screening","[{\"question\":\"Why are RAS oncogenes important targets in cancer therapy?\",\"answer\":\"RAS oncogenes such as NRAS, HRAS, and especially KRAS are among the most commonly mutated genes in cancer. Driver mutations activate RAS signaling by stabilizing the active, GTP-bound (ON) state, promoting oncogenic flux through downstream effectors.\"},{\"question\":\"What is RMC-7977 and what does it target?\",\"answer\":\"RMC-7977 is a reversible tri-complex RAS inhibitor designed to inhibit the active state of both mutant and wild-type RAS variants, including KRAS, NRAS and HRAS.\"},{\"question\":\"How did RMC-7977 perform in preclinical cancer models?\",\"answer\":\"In RAS-addicted preclinical models, RMC-7977 showed potent anti-tumor activity, including tumor regression, and was well tolerated. It also inhibited growth in KRAS(G12C) models that were resistant to KRAS(G12C) inhibitors by restoring RAS pathway signaling.\"}]","Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy | PDF",1790014454,71,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5509c87a7881a687a69e2ee8b0590b61.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/188be4a6b58b94824377b6a29abfe0c0.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/12f0b2b08a61550b3bffb3e9a84d0717.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/94815a36a9dca287d27e15547e07c72a.webp",980,1301]